Md. Code, Health - General § 13-3501
This is the official text of Md. Code, Health - General § 13-3501, part of Maryland’s Code, Health - General — covers public health regulation.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
§13–3501.
Official statutory text
(a) In this subtitle the following words have the meanings indicated.
(b) “Co–prescribing” means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.
(c) “Opioid overdose reversal drug” means naloxone or a similarly acting and equally safe drug that is approved by the federal Food and Drug Administration for the treatment of a known or suspected opioid overdose.
(b) “Co–prescribing” means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.
(c) “Opioid overdose reversal drug” means naloxone or a similarly acting and equally safe drug that is approved by the federal Food and Drug Administration for the treatment of a known or suspected opioid overdose.
Status: in_force · Read it on the official government site
Need a lawyer in Maryland?
Find a Maryland lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.